Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia

3rd July 2014

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE®) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow(1).

Read more at source article http://www.worldpharmanews.com – See more at: http://www.io-pharma.com/blog/fda-issues-guidance-to-support-the-responsible-development-of-nanotechnology-products/#sthash.2luBBSv1.dpuf


Leave a Reply

Your email address will not be published.

71 − = 61

« back to posts